drugset / Trial / NCT01549496

A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers

NCT01549496

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic interactions between the hepatitis C NS3 protease inhibitor boceprevir and the calcium channel blockers amlodipine and diltiazem in healthy volunteers.

Timeline

Start
2012-05
Primary completion
2012-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 2.5 mg
Subject Diltiazem Small molecule 120 mg